Last week, HemoAware was the first bleeding disorder non-profit to post the recent news regarding BioMarin's gene therapy data. Well, today the National Hemophilia Foundation finally got around to posting this on their website. However, they totally didn’t post any of the negative info from these trials. NHF failed to mention that there appears to be a plateau in year three and that BioMarin expects the gene therapy to control bleeding for eight years, not your entire lifetime. The info NHF published is misleading and gives false hope to the bleeding disorder community.